Romero, J. C., Tonapi, S. S., Parihar, M., Loranc, E., Miller, H. E., Lawrence, L. A., Bassani, N., Robledo, D. G., Cao, L., Nie, J., Kanda, K., Stoja, A., Garcia, N., Gorthi, A., Stoveken, B. J., Fan, T. W.-M., Cassel, T. A., Zha, S., Lechleiter, J. D., … Bishop, A. J. R. (2025). Loss of CD98HC phosphorylation by ATM impairs antiporter trafficking and drives glutamate toxicity in Ataxia telangiectasia. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-60304-4

Mitchell, J., Camacho, N., Shea, P., Stopsack, K. H., Joseph, V., Burren, O. S., Dhindsa, R. S., Nag, A., Berchuck, J. E., O’Neill, A., Abbasi, A., Zoghbi, A. W., Alegre-Díaz, J., Kuri-Morales, P., Berumen, J., Tapia-Conyer, R., Emberson, J., Torres, J. M., Collins, R., … Fabre, M. A. (2025). Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56944-1

Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J., Sclafani, C., Schmitz, J. C., Gore, S., Chu, E., Bakkenist, C. J., Beumer, J. H., & Villaruz, L. C. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-024-04745-6